

THE LAST DAY OF TRADING IN SUBSCRIPTION RIGHTS IN PROLIGHT'S RIGHTS ISSUE

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Today, June 25, 2025, is the last day of trading in subscription rights issued in connection with Prolight Diagnostics AB's (publ) ("Prolight" or the "Company") rights issue of shares which the board of directors resolved on May 21, 2025, and later approved by an Extraordinary General Meeting on June 10, 2025. Subscription rights that are not sold or used for subscription will expire worthless.

Summary of the Rights Issue

- The Rights Issue comprises 501,492,480 shares, corresponding to issue proceeds of approximately SEK 100.3 million.
- Anyone who was in the share register as a shareholder in Prolight on the record date of June 12, 2025, received one (1) subscription right for each one (1) share held. Seven (7) subscription rights entitle the holder to subscribe for five (5) new shares.
- The subscription price per share in the Rights Issue amounts to SEK 0.20.
- The subscription period for the Rights Issue runs from and including June 16, 2025, up to and including June 30, 2025.
- In total, the Rights Issue including the additional subscription commitments presented in the press release published on June 23, 2025, is covered by subscription commitments of approximately SEK 23.3 million, corresponding to approximately 23.2 percent of the Rights Issue.
- The full terms and conditions of the Rights Issue, including additional information about the Company, was made available in an information document pursuant to Annex IX of the Prospectus Regulation, published June 13, 2025.

Indicative timetable

June 16 – June 30, 2025	Subscription period in the Rights Issue
June 16 – July 16, 2025	Expected trading in paid subscribed shares (BTA) on NGM
July 2, 2025	Estimated date for announcement of issue outcome

Advisors

Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the Rights Issue.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Important Information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade shares, warrants or other securities in Prolight. No action has been taken and no action will be taken to allow an offer to the public in any jurisdiction other than Sweden. This press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 ("**Prospectus Regulation**"), and this press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Prolight. The information in this press release is only intended to describe the background to the exercise of the warrants and does not claim to be complete or exhaustive. No assurance shall be given with respect to the accuracy or completeness of the information in this press release.

The information in this press release may not be published, released or distributed, directly or indirectly, in or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require other actions than those following from Swedish law. Actions in violation of this instruction may constitute violations of applicable securities laws. No shares, warrants or other securities in Prolight have been registered, and no shares, warrants or other securities will be registered, under the then-applicable United States Securities Act of 1933 (the "**Securities Act**") or securities legislation in any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States except in accordance with an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with securities legislation in the relevant state or other jurisdiction in the United States.

The Company considers that it is engaged in activities worthy of protection under the Foreign Direct Investment Review Act (2023:560) (the "**FDI Act**"). In accordance with the FDI Act, the Company must inform prospective investors that the Company's activities may fall within the scope of the regulation and that the investment may be notifiable. If an investment is notifiable, it must be notified to the Swedish Inspectorate for Strategic Products (ISP) prior to its implementation. An investment may be notifiable if, after the investment is implemented, the investor, any member of its ownership structure or any person on whose behalf the investor is acting, holds voting rights equal to or exceeding any of the thresholds of 10, 20, 30, 50, 65 or 90 per cent of the total number of votes in the Company. An administrative fine may be imposed on the investor if a notifiable investment is made before the ISP has either: (i) decided to leave the notification without action; or (ii) approved the investment. Each shareholder should consult an independent legal advisor regarding the potential application of the FDI Law in relation to the Rights Issue for the individual shareholder.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "**relevant persons**"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Attachments

The last day of trading in subscription rights in Prolight's rights issue